KEYNOTE-001 Analysis Supports Pembrolizumab Use in Advanced MelanomaColin G. Evans, PhD
[1]http://abstracts.asco.org/214/CatView_214_S.html. [2]Ribas A, Puzanov I, Dummer R, ea al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015 Aug;16(8):908-18. [3] Ham...
PD-L1 and PD-L2 are expressed on the surface of tumor cells in many cancer types; PDL1 expression has been found both intracellularly and extracellularly in epithelial cancers, including melanoma and non-small cell lung cancer (NSCLC), and PD-L2 expression has been found in lymphoid ...
Objective Patients with melanoma and early stable disease (SD) with pembrolizumab have unclear prognosis. We present post hoc analyses of long-term outcomes for patients with early SD, partial response (PR)or complete response (CR) with pembrolizumab. Patients and methods Patients who received ...
Efficacy of pembrolizumab in patients with advanced mucosal melanoma enrolled in the KEYNOTE-001, 002, and 006 studies [ECCO abstract]. Eur J Cancer. 2017;72(suppl 1):S123.Butler M, Hamid O, Ribas A, Hodi FS, Walpole E, Dauad A, Arance A, Brown E, Hoeller C, Mortier L, ...